Bausch Health Companies Inc. (BHC) Announces the Commercial Expansion of OraPharma into Canada and Puerto Rico

Bausch Health Companies Inc. (NYSE:BHC) is one of the best cheap stocks under $10 to buy now. Bausch Health Companies Inc. (NYSE:BHC), along with its dental products business, announced the commercial expansion of OraPharma into Canada and Puerto Rico. Management reported that the strategic move highlights OraPharma’s commitment to bolster partnerships with dental professionals and local distributors in these markets, provide access to treatments in periodontal disease management, and improve oral health awareness.

OraPharma’s flagship product, Arestin®, is the only Food and Drug Administration (FDA) approved “applied antibiotic for use with scaling and root planing (SRP) as part of periodontal disease management”, indicated as an “as an adjunct to SRP for pocket depth reduction in adult periodontitis”.

Bausch Health Companies Inc. (NYSE:BHC) added that in Puerto Rico alone, 44.5% of older adults are living with moderate to severe periodontal disease, which highlights the need for improved access to treatment options in the region.

Bausch Health Companies Inc. (NYSE:BHC) develops, manufactures, and markets a range of generic, branded, and branded generic pharmaceuticals, over-the-counter products, and medical devices. The company’s operations are divided into the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb.

While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.